dr. wakelee on immunotherapy versus targeted agents in nsclc
Published 7 years ago • 289 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
1:46
dr. wakelee on single-agent immunotherapy in nsclc
-
2:18
dr. wakelee on first trial to combine antiangiogenesis agents with immunotherapy in nsclc
-
1:35
dr. wakelee on unmet needs for immunotherapy in nsclc
-
2:21
dr. wakelee on the rationale for immunotherapy in nsclc
-
3:04
final thoughts on targeted therapy and i/o agents in nsclc
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
1:23
dr. wakelee discusses current state of treatment in nsclc
-
1:19
dr. wakelee on combining targeted agents for the treatment of lung cancer
-
1:11
dr. borghaei on immunotherapy versus chemotherapy and immunotherapy in nsclc
-
2:15
dr. wakelee on birch trial for atezolizumab in patients with nsclc
-
1:29
dr. wakelee on available treatments following tumor progression in lung cancer
-
1:55
dr. heather wakelee discusses nintedanib plus chemotherapy in nsclc
-
1:54
dr. wakelee on fda approval of frontline pembrolizumab in nsclc
-
1:27
dr. wakelee discusses egfr tkis in lung cancer
-
1:40
dr. wakelee on immediate therapy options in lung cancer
-
7:00
novel immunotherapy combinations in nsclc
-
1:30
dr. papadimitrakopoulou on impactful targeted therapies in lung cancer
-
0:51
dr. leora horn on toxicities with immunotherapy in lung cancer
-
1:04
dr. carbone on the importance of personalizing immunotherapy in nsclc